| 000 -LEADER |
|---|
| fixed length control field |
a |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20181217113416.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
181217b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
AIKTC-KRRC |
| Transcribing agency |
AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| 9 (RLIN) |
7079 |
| Author |
Karmali, H. A. |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
DESIGN, SYNTHESIS, ANTIBACTERIAL AND ANTICANCER ACTIVITY OF 4-HYDROXY-3-(2-SUBSTITUTED-2-THIOXOETHYL)-1-PHENYL/ METHYLQUINOLIN-2(1H)-ONE DERIVATIVES |
| 250 ## - EDITION STATEMENT |
|---|
| Volume, Issue number |
Vol. 55 (11) November |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Mumbai |
| Name of publisher, distributor, etc. |
Indian Drug Manufacture's Association - IDMA |
| Year |
2018 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Pagination |
32-39p. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
A series of title compounds, 4-hydroxy-3-(2-substituted-2-thioxoethyl)-1-phenyl/methylquinolin-2(1H)- ones were synthesized and purity of the compounds was ascertained by TLC. The structures of the synthesized compounds were characterized by IR, NMR (1HNMR and 13CNMR) and mass spectral data. Molecular docking studies of the compounds were carried out using Molegro Virtual Docker. All the synthesized compounds were evaluated for anticancer activity against two different cell lines: K562 (leukemia) and A549 (lung cancer) and antibacterial evaluation was also carried out against Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Compound (II-a1) showed MIC of 1 μg/mL against B. subtilis and 4 μg/mL against S. aureus. Compound ( II-b1) showed MIC of 4 μg/mL against B. subtilis and 2 μg/mL against S. aureus gram positive bacterial strains. Compound II-a2 showed anticancer activity with IC50 value = 0.765 μM/mL against K562 cell line (leukemia) and II-a3 with IC50 value = 0.774 μM/mL. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
4639 |
| Topical term or geographic name entry element |
PHARMACEUTICS |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| 9 (RLIN) |
7080 |
| Co-Author |
Mamle Desai, S. N |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Indian drugs |
| Place, publisher, and date of publication |
Mumbai Indian Drug Manufactures Association |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| URL |
https://www.indiandrugsonline.org/issuesarticle-details?id=ODYy |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Koha item type |
Articles Abstract Database |
